EyePoint Pharmaceuticals Poised for Growth With Promising DME Treatment Duravyu
Some EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shareholders Look For Exit As Shares Take 27% Pounding
Selling EyePoint Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Express News | EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?
Baird Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $33
